Literature DB >> 7582297

Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction?

F A al-Kassimi1, M S al-Hajjaj, I O al-Orainey, E A Bamgboye.   

Abstract

A case-control study was conducted in Saudi Arabia, where the same strain of BCG has been used and surveys had shown that up to 88% of vaccinated children remain tuberculin negative. Active cases were obtained by surveying the seven tuberculosis centers in 1 yr. Control subjects were obtained from a nationwide survey of normal individuals. Vaccination in both groups was ascertained by history and BCG scar. Relative risk of contracting active tuberculosis in the vaccinated versus unvaccinated and protection was calculated. Protection was as follows: age group 5 to 14 yr, 82% (55 to 93%); age group 15 to 24 yr, 67% (55 to 77%); and age group 25 to 34 yr, 20% (-6 to 37%). We document the uninterrupted record of protection by BCG administered in the neonatal period and discuss the significance of vaccination timing. We concur with other studies that protection lapsed after about 20 yr. More importantly, this is the first large study that documents a lack of tuberculin sensitivity despite protection. This challenges the view that sensitization is essential for protection and supports the "two-pathway" theory that BCG vaccination could trigger either protective (Lister type) or antagonistic (tuberculin or Koch type) reactions and that the most protective vaccines would have little tuberculin-sensitizing effect because the two pathways are competitive.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582297     DOI: 10.1164/ajrccm.152.5.7582297

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  9 in total

1.  Tuberculin testing before BCG vaccination.

Authors:  Graham H Bothamley; Ed Cooper; Delane Shingadia; Alex Mellanby
Journal:  BMJ       Date:  2003-08-02

2.  Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.

Authors:  Lise Brandt; Joana Feino Cunha; Anja Weinreich Olsen; Ben Chilima; Penny Hirsch; Rui Appelberg; Peter Andersen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Novel human in vitro system for evaluating antimycobacterial vaccines.

Authors:  Beate Kampmann; Gwen N Tena; Shumikazi Mzazi; Brian Eley; Douglas B Young; Michael Levin
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Protective effect of BCG among children vaccinated under universal immunization programme.

Authors:  V K Chadha; L Suryanarayana; H V Suryanarayan; N Srikantaramu; P Kumar
Journal:  Indian J Pediatr       Date:  2004-12       Impact factor: 1.967

5.  The importance of animal models in tuberculosis vaccine development.

Authors:  Armando Acosta; Mohd Nor Norazmi; Rogelio Hernandez-Pando; Nadine Alvarez; Reinier Borrero; Juan F Infante; Maria E Sarmiento
Journal:  Malays J Med Sci       Date:  2011-10

6.  BCG vaccination at three different age groups: response and effectiveness.

Authors:  George Briassoulis; Irene Karabatsou; Vasilis Gogoglou; Athina Tsorva
Journal:  J Immune Based Ther Vaccines       Date:  2005-04-01

7.  Protective capacity of proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosis.

Authors:  Yanely Tirado; Alina Puig; Nadine Alvarez; Reinier Borrero; Alicia Aguilar; Frank Camacho; Fatima Reyes; Sonsire Fernández; José Luis Pérez; Dulce Mata Espinoza; Jorge Alberto Barrios Payán; María Elena Sarmiento; Mohd-Nor Norazmi; Rogelio Hernández-Pando; Armando Acosta
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines.

Authors:  Sergio Arregui; Joaquín Sanz; Dessislava Marinova; Carlos Martín; Yamir Moreno
Journal:  PeerJ       Date:  2016-02-11       Impact factor: 2.984

9.  Immunogenicity of recombinant Mycobacterium bovis bacille Calmette-Guèrin clones expressing T and B cell epitopes of Mycobacterium tuberculosis antigens.

Authors:  Rohimah Mohamud; Maryam Azlan; Daniel Yero; Nadine Alvarez; Maria E Sarmiento; Armando Acosta; Mohd-Nor Norazmi
Journal:  BMC Immunol       Date:  2013-02-25       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.